Therapeutic Solutions International (OTCMKTS:TSOI) Stock Rockets After Releasing New Data for QuadraMune®
Posted By Scott Birndorf on February 8, 2022
Monday turned out to be a momentous day for investors in Therapeutic Solutions International (OTCMKTS:TSOI) as a major announcement from the company led to a 34% jump in the stock price for the day.
Trading Data
On Monday, TSOI stock surged 34.15% to $0.0246 with more than 42.31 million shares, compared to its average volume of 8.49 million shares. The stock moved within a range of $0.0192 – 0.0284 after opening trade at $0.0193.
Therapeutic Solutions International Announces Reduction of COVID-19 Associated Cognitive Decline by QuadraMune® Nutraceutical in Animal Model
Yesterday, Therapeutic Solutions International announced that it had filed a fresh patent which included the data that showed administration of the product QuadraMune arrested the cognitive decline in mice who may have had a spike in COVID 19. It goes without saying that the development was a significant one for the company and the rally in the stock was perhaps understandable.
It is now going to be interesting to see if the Therapeutic Solutions International stock can manage to hold on to its momentum or if it suffers from a correction today. The data had been gleamed from a series of experiments that had been performed by Therapeutic Solutions International on mice.
The potential breakthrough could be a significant one and the fact that Therapeutic Solutions International filed for a patent could also be seen as a positive by many investors. At this point in time, it may be a good idea for investors to add the stock to their watch lists and watch the action.
Key Quote
“The more we learn about COVID-19 brain after-effects, the more we see a consistent pattern of inflammatory cytokines and inflammatory cells eliciting changes that cause chronic brain degeneration,” said Dr. Thomas Ichim, Board Member of Therapeutic Solutions International and Co-Inventor of the patent. “We are enthusiastic about the current data, which shows preservation of brain function and reduction of inflammation. This data suggests the possibility of offering a nutraceutical approach to COVID-19 patients to protect their brains.”
AI
